Immunotherapy in prostate cancer

Emily K. Fay, Julie N. Graff

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have shown impressive responses to cellular and immunotherapy. This review summarizes the current data for immunotherapy’s use in prostate cancer, as well as how currently available data might help predict patient responses to immunotherapy. Specifically, we will review vaccine-based therapies, immune checkpoint inhibitors, and future directions that are actively being explored.

Original languageEnglish (US)
Article number1752
Pages (from-to)1-17
Number of pages17
Issue number7
StatePublished - Jul 2020


  • Checkpoint inhibitor
  • Immunotherapy
  • Prostate cancer
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy in prostate cancer'. Together they form a unique fingerprint.

Cite this